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Introduction 
The water-soluble extract of the M. Charantia can sig-
nificantly reduce blood glucose concentrations in type-1 
diabetic rats [1]. Several studies have reported that the 
water-soluble extract of M. Charantia can exert anti-
cancerous activity through inhibition of DNA, RNA and 
cellular protein synthesis [2-4]. The fruit juice of M. 
Charantia has been found to increase glucose up take 
by several tissues in vitro and moreover, it can increase 
the storage of glycogen by the liver [5,6]. Paclitaxel is a 
natural product with antitumor activity. Paclitaxel is a 
diterpene alkaloid derived from the dried bark of Pacific 
yew tree Taxus brevifolia [7-9]. The chemical name for 
paclitaxel is 5β, 20-Epoxy-l, 2α, 4, 7β, 10β,13α-
hexahydroxytax-l l-en-9-one 4,10-diacetate 2-benzoate 
13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine. 
Paclitaxel is a white to off-white crystalline powder 
with the empirical formula C47H51NO14 and a molecular 
weight of 853.9 g/mol [9,10]. Paclitaxel is highly lipo-
philic, and melts at around 216-217°C and is used in 
treatment of various advanced carcinomas such as ovar-
ian cancer, lung cancer, breast cancer, acute leukemias, 
head and neck cancers and Kaposi’s sarcoma [11-13]. 
Paclitaxel is a mitotic inhibitor that blocks the prolifera-
tion of cancer celland is commercially available as Tax-
ol® that consists of Paclitaxel solubilised in Cremophor 
EL (polyethoxylated castor oil) and dehydrated alcohol 
(1:1v/v) [14-16]. Unfortunately, severe adverse reac-
tions like hypersensitivity reactions are caused by Cre-
mophor EL [17-19]. 
Correspondence: Dr. Gunasekar Manoharan, Chemistry Department, Faculty of Science, Jazan University,  
Al-Rawda District, Jazan, Saudi Arabia. Email: shekarphd@yahoo.com  
Materials and Methods 
Extraction method for either of α or β momorcharin: 
The whole fruit of bitter gourd was ground and homoge-
nized in 2 mM sodium phosphate buffer, pH 7.5. The 
resulting slurry was then stirred for 3 hrs to extract the 
crude proteins. The insoluble component from crude 
proteins was removed by the filtration and centrifuga-
tion at 30,000 x g for 1 hour at 48°C. By using 2 mM 
sodium phosphate buffer, pH 7.5, the crude protein so-
lution was dialysed. The dialysed protein sample was 
applied to DEAE Sepharose column equilibrated with 2 
mM sodium phosphate buffer at pH 7.5. The unbound 
proteins were then applied to Mono-S column which 
was equilibrated by 2 mM sodium phosphate buffer at 
pH 7.5 and eluted by 0.5 m of NaCl. [20]. The fraction 
corresponding to either alpha and beta or alpha, beta 
momorcharin, which was confirmed the N-glycoside 
activity RNA, was concentrated and dialysed against 20 
mM Tris-HCl buffer, pH 7.8. The chromatography was 
performed on Bio Logic DuoFlow system (BioRad, 
Hercules, CA) at 48°C. The purity of α and β momor-
charin was examined by SDS-PAGE and gel filtration 
chromatography. The concentration of alpha momor-
charin was determined by spectrophotometrically using 
optical absorbance at 280nm. 
Passaging of the Cancer cell lines and Control cell 
line 
The culture medium, phosphate buffer solution (PBS), 
and trypsin (sterile) were removed from the fridge at 
4oC and subsequently placed in the water bath at 37oC 
for 30 min in order to equilibrate. The Laminar flow 
hood was turned on for 15 min, prior to start of the ex-
periment, in order to purge the air inside the cabinet and 
to reach the maximum cleanliness. 
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Abstract 
The vegetable Momordica Charantia L., (family: Cucurbitaceae) is a scientific name of the plant and its fruit. It is 
also known by other names, for instance in the USA it is known as Bitter gourd or balsam pear while its referred to as 
the African cucumber in many African countries.  M. Charantia is believed to posse’s anti-carcinogenic properties 
and it can modulate its effect via xenobiotic metabolism and oxidative stress. This study was specifically designed to 
investigate the cellular mechanisms whereby α, β momorcharin an extract of M. Charantia can induce cell death with 
the combination of paclitaxel. Different concentration (200µM - 1000µM) of the α, β momorcharin fruit extract were 
treated (24 hrs. incubation) separately with three different cancer cell lines 1321N1, Gos-3, U87-MG and normal L6 
muscle cell line. The results also show that paclitaxel (250 µg) with (1000 µM) of the α, β momorcharin extract of M. 
Charantia, and result in significant decreases in cell viability for each cell line, these effects were additive compared 
to the individual effect of paclitaxel. 
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Three different cancer cell lines  (1321N1, Gos-3, U87-
MG) and L6 normal cell lines were incubated at 37°C 
incubator in an atmosphere of 5% CO2 in air. The cells 
were examined under the inverted contrast microscope 
to note the both confluence and general health of the 
cells.  The flask was passaged when the cells had 
reached 70-80% confluence. The medium was aspirated 
from the cultured flask and was washed with sterile PBS 
(5 ml if 75 cm2 flask and 2 ml if 25 cm2 flask) in order 
to remove any traces of serum from the cells. This pre-
vented the serum from inactivating the trypsin, which 
was used to detach adherent cells from the cell clump. 
Trypsin solution (2 ml if 75 cm2 flask or 1 ml if 25 cm2 
flask) was pipetted in the flask and incubated at 37°C in 
an incubator in an atmosphere of 5% CO2 in air for 3-5 
mins until the cells began to detach. The detachment 
was confirmed by observing at intervals under an invert-
ed microscope. The cells were left in the trypsin solu-
tion for the correct length of time. If the cells were left 
for a longer period of time then this would lead to dam-
age of the cells. A volume of 3 ml complete growth 
medium was then added to the flask to inactivate the 
trypsin and the cells were pipetted up and down to break 
up any large cell aggregates. The cell suspension was 
transferred from flask into 15 ml centrifuge tube and 
centrifuged at 1000 rpm for 5 min. Following centrifu-
gation, the supernatant was aspirated and the cells were 
pellet at the bottom of the centrifuge tube. Based upon 
the cell pellet density volumes of 1 ml to 3 ml fresh 
medium were suspended in the centrifuge tube. The cell 
pellet was flicked properly in the medium containing 20 
μl of trypsinised cell suspension and 80 μl of tryphan 
blue (used to detect dead cells in the cell suspension 1:5 
ratio). The contents were mixed well together and a 
haemocytometer test was performed using 1 ml of cell 
suspensions. This process helped to assess the total 
number of the cell suspension present in the centrifuge 
tube and which was required to make 1 or 2 flasks and 
to do 96 well plates. Thereafter, the cells were frozen in 
liquid nitrogen depending on the number of cells present 
per ml. The cell suspension was divided in either one or 
several flasks (depending on the cell density) and fresh 
growth medium (10 ml to 12 ml if 75 cm2 flask and 5 
ml if 25 cm2 flask) was added to the flasks. These were 
then placed in a 5% CO2 incubation.  
Preparation and application of α, β momorcharin 
extracts of M. Charantia on the cancer and L6 cell 
lines.  
Amounts of 14.51 mg, 29.25 mg, 43.53 mg, 58.50 mg, 
and 72.57 mg of either alpha or beta momorcharin and 
alpha, beta momorcharins (9.7 kDa) were weighed out 
separately in 5 ml universal vials and initially dissolved 
in 500 µl of phosphate buffer by continuous stirring and 
with the brief use of a sonicator water bath. These were 
then made up to 5 ml by adding 4.5 ml of the cell medi-
um to give concentrations 200 µM, 400 µM, 600 µM, 
800 µM, 1000 µM, respectively. The drug (extract) 
stock solution was transferred to a 10 ml syringe and 
sterile filtered using 0.22 µm filters into another sterile 
10 ml Universal bottles. These stock solutions were 
stored in a sealed tube in the fridge until required. Once 
removed from the fridge the prepared drug (extract) 
solutions were gently warmed in water bath at 37°C in 
order to ensure that the alpha, beta momorcharins was in 
a complete solution, before aliquoting. Volumes of 40 
μl, 80 μl, 120 μl, 160 μl, 200 μl contained 200 µM, 400 
µM, 600 µM, 800 µM, 1000 µM, respectively. Different 
concentrations of alpha beta momorcharins were trans-
ferred in triplicate using a Gilson pipette to 96 wells 
plate and the volume made to 200 μl by adding the cell 
media to both treated and control cell wells. Both con-
trol (untreated) and treated with (alpha beta momor-
charin) 96 well plates were incubated for 24 hrs.  
Dose dependent effects of paclitaxel on cancer cell 
line viability. 
In this series of experiments, different cancer cell lines 
(1231N1, Gos-3, U87-MG) and healthy L6 muscle cell 
line were incubated with the different concentrations of 
paclitaxel (50 - 250 µg) for 24 hours. Control cell lines 
were also incubated for the same period of time but 
without any paclitaxel. At the end of the incubation pe-
riod, cell viability of each cell line was measured using 
the MTS assay. 
Combined effects of either paclitaxel with the α, β 
momorcharin extract of   M. Charantia :  
Different cancer cell lines (1231N1, Gos-3, U87-MG) 
and healthy L6 muscle cell line were incubated either 
with paclitaxel (250 µg) and the α, β momorcharin ex-
tract of M. Charantia (1000 µM) or paclitaxel (250 µg) 
and 1000 µM) of the alpha, beta momorcharin for 24 
hours. Control cell lines were also incubated for the 
same time but without any drug or extract. At the end of 
the incubation period, cell viability of each cell line was 
measured using the MTS assay. 
Statistical Analysis: All control and test data collected 
from the different experiments were analysed using Sta-
tistical Package for Social Sciences (SPSS) version 17, 
Student’s t- test and ANOVA test. Data obtained were 
expressed as mean ± standard deviation (S.D). Each 
experiment was repeated for 4-6 times in duplicate (6 
for cell viability and 4 for cell signalling) to ensure the 
accuracy of results. A value of (p < 0.05) was taken as 
significant. 
Results  
Dose-dependent effects of paclitaxel on cell viability 
Figure 1 shows the effects of different concentrations 
(50 - 250 μg) of paclitaxel on the viability of the three 
different cancer cell lines and on healthy L6 skeletal 
muscle cell line employed in this study. Also shown in 
the figure 1 are the untreated three different cancer cell 
lines and healthy L6 skeletal muscle cell line for com-
parison. All the cells were treated with paclitaxel for 24 
hours. Each control cell lines were also incubated for 24 
hrs but with no paclitaxel. The results show that in all 
three different cancer cell lines (1321N1, Gos-3, U87-
MG), paclitaxel can evoke marked and significant (p < 
0.05) decreases in the cell viability (cell death) com-
pared to untreated cells (100% viability). These effects 
of the paclitaxel were dose-dependent with maximal cell 
death occurring with 250 μg. Similarly, paclitaxel sig-
nificantly (p < 0.05) decreased the viability of healthy 
L6 skeletal muscle cell line compared to untreated L6 
cell line but mainly at a high dose. The results also show 
that paclitaxel was more effective in killing 1321N1 and 
Gos-3, cell lines. It has less effective on U87-MG cell 
line, which seems to be more resistant to the drug. The 
surprised finding in this study was that paclitaxel could 
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Int. J. Curr.  Res. Physiol. Pharmacol. 2019;3(2):2-6. 
 4 
 
also kill healthy L6 skeletal muscle cell compared to the 
α, β momorcharin extract of M. Charantia, which had 
no detectable effect on the viability of L6 cell line.  
Combined effects of α, β momorcharin extract of M. 
Charantia with paclitaxel  
Figure 2 shows the effect of paclitaxel (250 μg) alone or 
the α, β momorcharin extract of M. Charantia (1000 
µM, a high dose) alone or a combination of paclitaxel 
(250 μg) with the α, β momorcharin extract of M. Char-
antia (1000 µM) on the viability of the three different 
cancer cell lines and on healthy L6 skeletal muscle cell 
line employed in this study. Also shown in the figure 2 
are the untreated three different cancer cell lines and 
healthy L6 skeletal muscle cell line for comparison. All 
the cells were treated with paclitaxel and α, β momor-
charin extract of M. Charantia (drug + extract) for 24 
hours. Control cell lines were also incubated for the 
same time. The results show that in all three different 
cancer cell lines (1321N1, Gos-3, U87-MG,) either 
paclitaxel or α, β momorcharin extract of M. Charantia 
can evoked marked and significant p < 0.05 decreases in 
the cell viability (cell death) compared to untreated cells 
(100% viability). However, when paclitaxel was com-
Figure 1. Dose-dependent effects of paclitaxel 
Figure 2. Effect of either of 250 μg paclitaxel alone or 1000 µM of α, β momorcharin of M. Charantia alone 
and combination of paclitaxel (250 μg) with α, β momorcharin extract of M. Charantia (1000 µM) on the via-
bility of three different cancer cell lines  
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bined with the α, β momorcharin extract of M. Char-
antia, there was a further decrease in cell viability. 
These values were significantly (p < 0.05) different 
compared to either untreated cells (100%) or cell treated 
with either paclitaxel or α, β momorcharin extract of M. 
Charantia. 
Similarly, paclitaxel combined with the α, β momor-
charin extract of M. Charantia can evoke significant (p 
< 0.05) decrease in the death of healthy L6 skeletal 
muscle cell line. The results also show that combined 
drugs (drug + extract) were more effective in killing 
1321N1, Gos-3, cell lines. It has less effective on U87-
MG cell lines. 
Discussion  
This study employed the α, β momorcharin extracts of 
M. Charantia, and commercially available anti-cancer 
drugs paclitaxel to investigate their effects on the viabil-
ity (cell death) of three different cancer cell lines com-
pared to healthy L6 skeletal muscle cell line. Either the 
α, β momorcharin extract of M. Charantia, paclitaxel 
was tested alone measuring the viability of each cell 
line. In some experiments, paclitaxel was combined 
with α, β momorcharin extracts of M. Charantia, to in-
vestigate any potentiating or attenuating effect on cell 
viability. The rationale for this study was that M. Char-
antia, a local plants-base (herbal) medicine could be 
used to treat different types of cancers. The results of 
the present study have shown that either paclitaxel can 
significantly decrease the viability of 1321N1, Gos-3, 
U87-MG, cancer cell lines. Both anti-cancer drugs also 
decreased the viability of healthy L6 skeletal muscle 
cell line. The effect of each drug was dose–dependent 
with maximal effect occurring at paclitaxel. The results 
of this study also show that combining a moderate to a 
high dose of paclitaxel with a high dose of either the α, 
β momorcharin extract of M. Charantia only produce a 
small, but significant decrease in the viability of each 
cancer cell line compared to the effect of paclitaxel and 
the α, β momorcharin extract of M. Charantia alone. 
This small decrease in cell viability of each cell line was 
slightly significant, but it was neither additive nor syn-
ergetic compared to the separate effect of each. This 
was a rather surprising result in this study.   
Conclusion 
In conclusion, the results of this study have clearly 
demonstrated that the α, β momorcharin extract of M. 
Charantia can evoke significant decreases in cancer cell 
viability (an increase in cell death) without killing 
healthy cell line like L6 skeletal muscle cell line. Either 
paclitaxel with maximal effect of paclitaxel can also 
elicit dose-dependent decreases in cancer cell viability. 
Combining paclitaxel with either the α, β momorcharin 
extract of M. Charantia had no additive or synergetic 
effect on the viability of each cell line compared to the 
effect of either alone. It is concluded that extracts of M. 
Charantia possess anti-cancer properties since they can 
induce cell death.  
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